M.E. Allison & Co’s Myriad Genetics MYGN Stock Holding History

M.E. Allison & Co’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,520	Closed	-$93.3K	–	174
2025 Q1	$93.3K	Buy	+10,520	New	+$126K	0.09%	153

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

M.E. Allison & Co's MYGN Position: Q2 2025 in Review

M.E. Allison & Co sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 10,520 shares — an estimated $93.3K sold.

M.E. Allison & Co first reported a position in MYGN in Q1 2025 and held it in 1 quarter. The position peaked at $93.3K in Q1 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

M.E. Allison & Co reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
M.E. Allison & Co sold 10,520 Myriad Genetics shares in Q2 2025, an estimated $93.3K.
M.E. Allison & Co first reported a position in Myriad Genetics in Q1 2025 and held it in 1 quarter.
M.E. Allison & Co's Myriad Genetics position peaked at $93.3K in Q1 2025.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on M.E. Allison & Co's 13F filing for Q2 2025, filed 25 Jul 2025.